Autologous hematopoietic stem cell transplantation for systemic sclerosis

Current Stem Cell Research and Therapy

Volumn 6, Issue 1, 2011, Pages 16-28

  Milanetti, Francesca ^a   Bucha, Jurate ^a   Testori, Alessandro ^a   Burt, Richard K ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hematopoietic stem cell; Scleroderma; Systemic sclerosis; Transplantation

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CENTROMERE PROTEIN B; CHLOROQUINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; ENDOTHELIAL CELL ANTIBODY; FIBRILLIN 1; MATRIX METALLOPROTEINASE; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; RAS PROTEIN; SCL 70 ANTIBODY;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; COMPARATIVE STUDY; ENDOTHELIAL PROGENITOR CELL; FORCED VITAL CAPACITY; HEART OUTPUT; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG FUNCTION; LUNG VASCULAR RESISTANCE; MORPHEA; MORTALITY; PATHOGENESIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN FIBROSIS; SKINFOLD THICKNESS; SURVIVAL; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; VASCULAR DISEASE; WHOLE BODY RADIATION;

CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIVARIATE ANALYSIS; SCLERODERMA, SYSTEMIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 79551661809     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488811794480663     Document Type: Article

References (108)

1. Helmick CG, Felson DT, Lawrence RC, et al. National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58(1): 15-25.
2. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004; 43: 596-602.
3. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991; 283: 366-71.
4. Roberts-Thomson PJ, Walker JG, Lu TY, et al. Scleroderma in South Australia: further epidemiological observations supporting a stochastic explanation. Intern Med J 2006; 36 (8): 489-97.
5. Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EU-LAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66(6): 754-63.
6. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23(5): 581-90.
7. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 1988; 15: 202.
8. Goetz RH, Berne MB. The pathophysiology of progressive systemic sclerosis (generalized scleroderma) with special reference to changes in the viscera. Clin Proc 1945; 4: 337-92
9. Tuffanelli DL, Winkelmann RK. Diffuse systemic scleroderma. A comparison with acrosclerosis. Ann Intern Med 1962; 57: 198-203.
10. Winterbauer RH. Multiple teleangiectasia. Raynauds phenomenon, sclerodactily and subcutaneous calcinosis: a syndrome mimicking hereditary hemorrhagic teleangiectasia. Bull Johns Hopkins Hosp 1964; 114: 361-83.
11. Barnett AJ, Coventry DA., Scleroderma I. Clinical features, course of illness and response to treatment in 61 cases. Med J Aust 1969; 1(19): 992-1001.
12. Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis. Clin Rheum Dis 1979; 5: 5-13.
13. Giordano M, Valentini G, Migliaresi S, Picillo U, Vatti M. Different antibody patterns and different prognosis in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 1986; 13: 911-6.
14. Holzmann H, Sollberg S, Altmeyer P. Classification of progressive systemic scleroderma. Hautarzt 1987; 38(5): 253-7.
15. Masi AT. Classification of systemic sclerosis (scleroderma): Relationship of cutaneous subgroups in early disease to outcome and se-rologic reactivity. J Rheumatol 1988; 15: 894-8.
16. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28(7): 1573-6.
17. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine(Baltimore) 2002; 81(2): 139-53.
18. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81(2): 154-67.
19. Maricq HR, Valter I. A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 2004; 22 (3 Suppl 33): S5-13.
20. Nishimagi E, Kawaguchi Y, Tanaka E, Hara M, Kamatani N. Classification of systemic sclerosis in the Japanese population based on rapid progression of skin thickening. Mod Rheumatol 2004; 14(3): 216-21.
21. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47(8): 1185-92.
22. Johnson SR, Feldman BM, Hawker GA. Classification criteria for systemic sclerosis subsets. J Rheumatol 2007; 34(9): 1855-63.
23. Clements P, Lachenbruch P, Seibold JR, et al. Inter- and intraob-server variability of total skin thickness score (modified Rodan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-1285.
24. Hanitsch LG, Burmester GR, Witt C, et al. Skin sclerosis is only of limited value to identify SSc patients with severe manifestations--an analysis of a distinct patient subgroup of the German Systemic Sclerosis Network (DNSS)Register. Rheumatology (Oxford) 2009; 48(1): 70-3
25. Shand L, Lunt M, Nihtynova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis. Application of a latent linear trajectory model. Arthritis Rheum 2007; 56: 2422-31d.
26. Maricq HR. widefield capillary microscopy. Technique and rating scale for abnormalities seen in scleroderma and related disorders. Arthritis Rheum 1981; 24; 1159-65.
27. Avouac J, Juin F, Wipff J, et al. Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity. Ann Rheum Dis 2008; 67(10): 1455-60.
28. Avouac J, Wipff J, Goldman O, et al. Angiogenesis in systemic sclerosis: impaired expression of vascular endothelial growth factor receptor 1 in endothelial progenitor-derived cells under hypoxic conditions. Arthritis Rheum 2008; 58(11): 3550-61.
29. Koenig M, Dieudé M, Senécal JL. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008; 7(8): 588-93.
30. Bordron A, Dueymes M, Levy Y, et al. The binding of some human antiendothelial cell antibodies induces endothelial apoptosis. J Clin Invest 1996; 101: 2029-35.
31. Ahmed SS, Tan FK, Arnett FC, et al. Scleroderma sera containing endothelial cell antibodies induce apoptosis and fibrillin-1 in human dermal endothelial cells. Arthritis Rheum 2006; 54: 2250-62.
32. Tan FK, Arnett FC, Reveille JD, et al. Autoantibodies to fibrillin-1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000; 43: 2464-71.
33. Zhou X, Tan FK, Wallis D, et al. Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF beta pathway and recapitulate the 'scleroderma phenotype'. J Immunol 2005; 175: 4555-60.
34. Sato S, Hayakawa I, Hasegawa M, et al. Function blocking autoan-tibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 2003; 120: 542-547.
35. Nishijima C, Hayakawa I, Matsushita T, et al. Autoantibody against matrix metalloproteinase-3 patients with systemic sclerosis. Clin Exp Immunol 2004; 138:357-363.
36. Svegliati Baroni S, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-76.
37. Tan FK. Autoantibodies against PDGF receptor in scleroderma [editorial]. N Engl J Med 2006; 354: 2709-11.
38. Pope JE, Thompson A. The frequency and significance of anticar-diolipin antibodies in scleroderma. J Rheumatol 2000; 27: 1450-2.
39. Kane D, McSweeney F, Swan N, Bresnihan B. Catastrophic an-tiphospholipid syndrome in primary systemic sclerosis. J Rheuma-tol 1998; 25: 810-12.
40. hn H, Sato S, Fujimoto M, Kikuchi K, et al. Measurement of anti-cardiolipin antibodies by ELISA using b2-glycoprotein I (b2-GPI) in systemic sclerosis. Clin Exp Immunol 1996; 105: 475-9.
41. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118(1): 2-10.
42. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-5.
43. Czirjak L, Nagy Z, Szegedi G. Survival analysis of 118 patients with systemic sclerosis. J Intern Med 1993; 234: 335-7.
44. Nagy Z, Czirjak L. Predictors of survival in 171 patients with systemic sclerosis (scleroderma). Clin Rheumatol 1997; 16: 454-60.
45. Nagy Z, Czirjak L. Increased C reactive protein and aminotermi-nal propeptide of type III procollagen levels are unfavourable predictors of survival in systemic sclerosis (scleroderma). Clin Exp Rheumatol 2005; 23: 165-72.
46. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001; 28: 2454-9.
47. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998; 57: 682-6.
48. Jacobsen S, Halberg P, Ullman S. Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma). Br J Rheumatol 1998; 37: 750-5.
49. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis. Arthritis Rheum 2000; 43: 2445-54.
50. Wynn J, Fineberg N, Matzer L, et al. Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 1985; 110: 123-7.
51. Zarafonetis CJ, Dabich L, Negri D, Skovronski JJ, DeVol EB, Wolfe R. Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. J Clin Epidemiol 1988; 41: 193-205.
52. Medsger TA Jr, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chron Dis 1973; 26: 647-60.
53. Simeon CP, Armadans L, Fonollosa V, et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Ann Rheum Dis 2003; 42: 71-5.
54. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
55. Bulpitt KJ, Clements PJ, Lachenbruch PA, et al. Early undifferen-tiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 1993; 118: 602-9.
56. Farmer RG, Gifford RW, Hines EA. Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma. Circulation 1960; 21: 1088-95.
57. Geirsson ÁJ, Wollheim FA, Akesson A. Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis 2001; 60: 1117-22.
58. Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada. Semin Arthritis Rheum 2010; 39(4); 269-77.
59. Czirják L, Kumánovics G, Varjú C, et al. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis 2008; 67(1): 59-63.
60. Majewski S, Wojas-Pelc A, Malejczyk M, Szymanska E, Jablonska S. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Acta Derm Venereol 1999; 79(3): 207-210.
61. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 2001; 44(12): 2828-35.
62. Hachulla E, de Groote P, Gressin V, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60(6): 1831-9.
63. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44:1351-8
64. Van den Hoogen FH, Boerbooms AM, Swaak AJ, Rasker JJ, van Lier HJ, van de Putte LB. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-72
65. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 1999; 42(6): 1194-203.
66. Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41(9): 1613-9.
67. Clements PJ, Sterz M, Danovitch G, et al. Cyclosporin (CsA) in systemic sclerosis (SSc): Results of a 48-week open safety study in 10 SSc patients. Arthritis Rheum 1993; 36: 75-83.
68. O'Dell JR, Steigerwald JC, Kennaugh RC, Hawkins R, Holers VM, Kotzin BL. Lack of clinical benefit after treatment of systemic sclerosis with total lymphoid irradiation. J Rheumatol 1989; 16(8): 1050-4.
69. Hoyles RK, Ellis RW, Wellsbury J et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticos-teroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006; 54(12): 3962-70.
70. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354(25): 2655-66.
71. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176(10): 1026-34.
72. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 2006; 25: 205-12.
73. Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclo-phosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008; 10(5): R124
74. Hunzelmann N, Moinzadeh P, Genth E, et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009; 11(2): R30.
75. Pope JE, Ouimet JM, Krizova A. Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum 2006; 55: 138-145.
76. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophos-phamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 947-54.
77. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J. Rheumatol 2002; 29: 731-6.
78. Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol 2002; 29: 298-304.
79. Beretta L, Caronni M, Raimondi M, et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibros-ing alveolitis: experience in one centre. Clin Rheumatol 2007; 26: 168-72.
80. Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathio-prine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008; 35(6): 1064-72.
81. Burt RK, Loh Y, Pearce W, et al. J. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008; 299(8): 925-36.
82. Frère P, Pereira M, Fillet G, Beguin Y. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol 2006;76(2): 102-8.
83. Burt RK, Marmont A, Oyama Y, et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lym-phoablative transplant regimens. Arthritis Rheum 2006; 54(12): 3750-60.
84. Montoto S, Canals C, Rohatiner AZ, et al. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia 2007; 21(11): 2324-31.
85. Emerit I, Housset J, De Grouchy J, Carnus JP. Chromosomal breakage in diffuse scleroderma. A study of 27 patients. Eur J Clin Biol Res 1971; 16: 683-94.
86. Pan SF, Rodnan GP, Seutsch M, Wald N. Chromosomal abnormalities in progressive systemic sclerosis (scleroderma) with consideration of radiation effects. J Lab Clin Med 1975; 86: 300-8.
87. Rittner G, Schwanitz G, Baur MP, et al. Family studies in scleroderma (systemic sclerosis) demonstrating an HLA-linked increased chromosomal breakage rate in cultured lymphocytes. Hum Genet 1988; 81: 64-70.
88. Migliore L, Bevilacqua C, Scarpato R. Cytogenetic study and FISH analysis in lymphocytes of systemic lupus erythematosus and systemic sclerosis patients. Mutagenesis 1999; 14: 227-31.
89. Artlett CM, Black CM, Briggs DC, Stevens CO, Welsh KI. Te-lomere reduction in scleroderma patients: a possible cause for chromosomal instability. Br J Rheumatol 1996; 35: 732-7.
90. Wolff DJ, Needleman BW, Wasserman SS, Schwarts S. Spontaneous and clastogen induced chromosomal breakage in scleroderma. J Rheumatol 1991; 18: 837-40.
91. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immuno-suppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110(4): 1388-96.
92. Bohgaki T, Atsumi T, Bohgaki M, et al. Immunological reconstitu-tion after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression. J Rheumatol 2009; 36(6): 1240-8.
93. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201(5): 805-16.
94. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009; 113(1): 214-23.
95. Zhang L, Bertucci AM, Ramsey-Goldman R, Burt RK, Datta SK. Regulatory T cell (TReg) subsets return in patients with refractory lupus following adult stem cell transplantation: TGF-p producing CD8+ Treg (CD8TGF-(3 Treg) are associated with suppressing lupus into immunologic remission. J immunol 2009; 183(10): 6346-58.
96. Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60(6): 577-84.
97. Farge D, Marolleau JP, Zohar S, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002; 119(3): 726-39.
98. McSweeney PA, Nash RA, Sullivan KM, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100(5): 1602-10.
99. Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63(8): 974-81.
100. Tsukamoto H, Nagafuji K, Horiuchi T, et al. A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006; 65(4): 508-14.
101. Oyama Y, Barr WG, Statkute L, et al. Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. Bone Marrow Transplant 2007; 40(6): 549-55.
102. Vonk MC, Marjanovic Z, van den Hoogen FH et al. Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. Ann Rheum Dis 2008; 67(1): 98-104.
103. Englert H, Kirkham S, Moore J, et al. Autologous stem cell transplantation in diffuse scleroderma: impact on hand structure and function. Intern Med J 2008; 38(9): 692-6
104. Fleming JN, Nash RA, McLeod DO, et al. Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 2008; 3(1): e1452.
105. Miniati I, Guiducci S, Conforti ML, et al. Autologous stem cell transplantation improves microcirculation in systemic sclerosis. Ann Rheum Dis 2009; 68(1): 94-8.
106. http://www.astistrial.com
107. http://www.clinicaltrials.gov (NCT00114530)
108. http://www.clinicaltrials.gov (NCT00278525)